INSYS Therapeutics Inc. (INSY)

0.30
0.01 4.52
OTC : Health Technology
Prev Close 0.29
Open 0.28
Day Low/High 0.28 / 0.32
52 Wk Low/High 0.14 / 11.65
Volume 1.09M
Avg Volume 3.70M
Exchange OTC
Shares Outstanding 74.57M
Market Cap 21.71M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Insys Therapeutics is Now Oversold (INSY)

Insys Therapeutics is Now Oversold (INSY)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Purchase Insys Therapeutics At $6, Earn 24% Annualized Using Options

Commit To Purchase Insys Therapeutics At $6, Earn 24% Annualized Using Options

Investors eyeing a purchase of Insys Therapeutics Inc shares, but cautious about paying the going market price of $7.37/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $6 strike, which has a bid at the time of this writing of 45 cents.

Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers

Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers

The clinical-stage biopharmaceutical firm said Oct. 16 it has priced an underwritten public offering of five million shares at $16 apiece.

INSYS Therapeutics Extends 'Compassionate Use' Studies Of Cannabidiol (CBD) For Refractory Pediatric Epilepsy

INSYS Therapeutics Extends 'Compassionate Use' Studies Of Cannabidiol (CBD) For Refractory Pediatric Epilepsy

Extension of Expanded Access Program Enables Patients from Initial Trials to Continue Taking Investigational Medicine Under Their Physicians' Supervision

INSYS Therapeutics Completes Pharmacokinetics (PK) Study Of Intranasal Naloxone For Opioid Overdose

INSYS Therapeutics Completes Pharmacokinetics (PK) Study Of Intranasal Naloxone For Opioid Overdose

Results Show Favorable Effect of Company's Novel Formulation, Similar to Intramuscular Administration; NDA Filing with FDA on Track for 2018

INSYS Therapeutics Files New Drug Application (NDA) For Buprenorphine Sublingual Spray With FDA

INSYS Therapeutics Files New Drug Application (NDA) For Buprenorphine Sublingual Spray With FDA

Advances R&D for promising portfolio of innovative medicines

Insiders Now Seeing Red With INSY At New 52-Week Low

Insiders Now Seeing Red With INSY At New 52-Week Low

In trading on Monday, shares of Insys Therapeutics Inc touched a new 52-week low of $8.68/share. That's a $6.38 share price drop, or -42.36% decline from the 52-week high of $15.06 set back on 11/10/2016.

INSYS Therapeutics Hires First Corporate Communications Leader And New Investor Relations Agency

INSYS Therapeutics Hires First Corporate Communications Leader And New Investor Relations Agency

Increases commitment to engaging key stakeholder groups as Company continues development of pharmaceutical cannabinoids

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARCI, GRC, HDNG, PLPC Downgrades: AFI, CXW, DEL, HBMD, INSY, JCAP, MET, NGVC, PLT, SATS, STRL, UHS, VRTV, WP Initiations: PI, VRS Read on to get TheStreet Quant Ratings' detailed report:

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)

Jim Cramer says the calendar and the momentum holders are coalescing to produce selling. Here's what investors should do about it.

Insys Therapeutics Shares Cross Below 200 DMA

Insys Therapeutics Shares Cross Below 200 DMA

In trading on Friday, shares of Insys Therapeutics Inc crossed below their 200 day moving average of $11.34, changing hands as low as $11.17 per share. Insys Therapeutics Inc shares are currently trading off about 1.6% on the day.

September 15th Options Now Available For Insys Therapeutics (INSY)

September 15th Options Now Available For Insys Therapeutics (INSY)

Investors in Insys Therapeutics Inc saw new options begin trading today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new September 15th contracts and identified one put and one call contract of particular interest.

Alder Shares Plummet Almost 25% Despite Positive Data; Aralez Pops on Patent Victory: Biotech Movers

Alder Shares Plummet Almost 25% Despite Positive Data; Aralez Pops on Patent Victory: Biotech Movers

Alder BioPharmaceuticals, Aralez Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on June 27.

Interesting INSY Put And Call Options For February 2018

Investors in Insys Therapeutics Inc saw new options begin trading this week, for the February 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Opioid Marketing Under Bipartisan Investigation

Opioid Marketing Under Bipartisan Investigation

Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

The FDA requested Endo to remove its opioid pain medication from the market, expressing concern that the "benefits of the drug may no longer outweigh its risks."

Launch of Cannabis ETF May Not Be Best Option for Investors

Launch of Cannabis ETF May Not Be Best Option for Investors

Although a cannabis ETF launched in April, investors are still likely to find more value in buying individual stocks in the sector, according to traders.